Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged.
Alabraba E, Joshi H, Bird N, Griffin R, Sturgess R, Stern N, Sieberhagen C, Cross T, Camenzuli A, Davis R, Evans J, O'Grady E, Palmer D, Diaz-Nieto R, Fenwick S, Poston G, Malik H.
Alabraba E, et al.
Eur J Surg Oncol. 2019 Sep;45(9):1660-1667. doi: 10.1016/j.ejso.2019.04.002. Epub 2019 Apr 9.
Eur J Surg Oncol. 2019.
PMID: 31014988